Study study type PathologyT1T0Patientssample sizesROB Results

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

versus Standard of Care (SoC)
atezolizumab alone
IMpower-110 (TC1/2/3 or IC1/2/3), 2020
  NCT02409342
RCTmNSCLC - L1 - PDL1 positiveatezolizumabplatinium chemotherapyPD-L1–selected patients (positive for PD-L1 on the SP142 assay) with EGFR and ALK wild-type metastatic NSCLC who had not previously received chemotherapy. (TC 1/2/3)277 / 277some concern
inconclusive
  • inconclusive 17 % decrease in deaths (OS) (PE)
  • suggested 28 % decrease in PFS (extension)
  • suggested 23 % decrease in progression or deaths (PFS)
IMpower-110 (TC3 or IC3), 2020
 
NCT02409342
RCTmNSCLC - L1 - PDL1 positiveatezolizumabplatinum chemotherapyPD-L1–selected patients (positive for PD-L1 on the SP142 assay) with EGFR and ALK wild-type metastatic NSCLC who had not previously received chemotherapy. (TC 3)107 / 98some concern
conclusif
  • demonstrated 41 % decrease in deaths (OS) (PE)
  • suggested 41 % decrease in PFS (extension)
  • suggested 37 % decrease in progression or deaths (PFS)
IMpower-110 (TC2/3 or IC2/3), 2020
 
NCT02409342
RCTmNSCLC - L1 - PDL1 positiveatezolizumabplatinium chemotherapyPD-L1–selected patients (positive for PD-L1 on the SP142 assay) with EGFR and ALK wild-type metastatic NSCLC who had not previously received chemotherapy. (TC2/3)166 / 162some concern
suggested
  • suggested 28 % decrease in deaths (OS) (PE)
  • suggested 36 % decrease in PFS (extension)
  • suggested 33 % decrease in progression or deaths (PFS)

non squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - all population

versus atezolizumab plus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel
IMpower-130 (all population), 2019
  NCT02367781
RCTnon squamous - mNSCLC - L1 - all populationatezolizumab plus carboplatin plus nab-paclitaxel (ACnp)carboplatine plus nab-paclitaxel (CnP)first-line therapy for patients with stage IV non-squamous nonsmall- cell lung cancer and no ALK or EGFR mutations who have not previously received chemotherapy483 / 240some concern
conclusif
  • demonstrated 20 % decrease in deaths (OS) (PE)
  • demonstrated 35 % decrease in progression or deaths (PFS) (PE)
versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018
  NCT02366143
RCTnon squamous - mNSCLC - L1 - all populationatezolizumab and bevacizumab, carboplatin plus paclitaxel (ABCP)bevacizumab plus carboplatin plus paclitaxel (BCP)patients with stage IV or recurrent metastatic nonsquamous NSCLC who had not previously received chemotherapy.400 / 400some concern
inconclusive
  • suggested 24 % decrease in deaths (OS)
  • suggested 39 % decrease in progression or deaths (PFS)
atezolizumab plus carboplatin plus paclitaxel
IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018
  NCT02366143
RCTnon squamous - mNSCLC - L1 - all populationatezolizumab plus carboplatin plus paclitaxel (ACP)bevacizumab and caroplatin plus paclitaxel (BCP)patients with stage IV or recurrent metastatic nonsquamous NSCLC who had not previously received chemotherapy.402 / 400some concern
inconclusive
    no statistically significant result

non squamous - mNSCLC - L1 - Wild Type (WT) metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - Wild Type (WT)

versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018
  NCT02366143
RCTnon squamous - mNSCLC - L1 - Wild Type (WT)atezolizumab and bevacizumab, carboplatin plus paclitaxel (ABCP)bevacizumab plus carboplatin plus paclitaxel (BCP)patients with stage IV or recurrent metastatic nonsquamous NSCLC who had not previously received chemotherapy.155 / 129some concern
conclusif
  • demonstrated 49 % decrease in progression or deaths (PFS) (PE)
IMpower-150 (ABCP vs BPC WT), 2018
  NCT02366143
RCTnon squamous - mNSCLC - L1 - Wild Type (WT)atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP)bevacizumab and caroplatin plus paclitaxel (BCP)patients with stage IV or recurrent metastatic nonsquamous NSCLC who had not previously received chemotherapy.356 / 336some concern
conclusif
  • demonstrated 22 % decrease in deaths (OS) (PE)
  • demonstrated 38 % decrease in progression or deaths (PFS) (PE)
versus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel
IMpower-130 (WT), 2019
  NCT02367781
RCTnon squamous - mNSCLC - L1 - Wild Type (WT)atezolizumab (ACnP) plus carboplatine plus nab-paclitaxelcarboplatine plus nab-paclitaxelfirst-line therapy for patients with stage IV non-squamous nonsmall- cell lung cancer who have not previously received chemotherapy. (EGFRwt and ALKwt)451 / 228some concern
conclusif
  • demonstrated 21 % decrease in deaths (OS) (PE)
  • demonstrated 36 % decrease in progression or deaths (PFS) (PE)
  • statistically significant 1.4-fold increase in DOR
versus pemetrexed plus platin
atezolizumab plus pemetrexed and platin
IMpower-132 (WT) unpublished
 
NCT02657434
RCTnon squamous - mNSCLC - L1 - Wild Type (WT)Atezolizumab (induction and maintenance) plus pemetrexed plus platinepemetrexed plus platineChemotherapy-naive patients with Stage IV non-squamous NSCLC without EGFR or ALK genetic alteration292 / 286NA
conclusif
  • inconclusive 19 % decrease in deaths (OS) (PE)
  • demonstrated 40 % decrease in progression or deaths (PFS) (PE)

squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) squamous cell - mNSCLC - L1 squamous - mNSCLC - L1 - all population

versus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel
IMpower-131 (ACnP), 2020
  NCT02367794
RCTsquamous - mNSCLC - L1 - all populationatezolizumab plus carboplatine plus nab-paclitaxel(ACnP)carboplatine plus nab-paclitaxel (CnP)chemotherapy-naive participants with Stage IV squamous NSCLC343 / 340some concern
conclusif
  • inconclusive 12 % decrease in deaths (OS) (PE)
  • demonstrated 29 % decrease in progression or deaths (PFS) (PE)
  • statistically significant 1.1-fold increase in DOR